Benefit-Risk Assessment of Linezolid for Serious Gram-Positive Bacterial Infections

Author： Falagas Matthew E.   Vardakas Konstantinos Z.  

Publisher： Adis International

ISSN： 0114-5916

Source： Drug Safety, Vol.31, Iss.9, 2008-01, pp. : 753-768

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Linezolid: A Pharmacoeconomic Review of its Use in Serious Gram-Positive Infections

By Plosker Greg L.   Figgitt David P.  

PharmacoEconomics, Vol. 23, Iss. 9, 2005-01 ,pp. : 945-964

Adis International

Access to resources Recommend Favorite

Linezolid: A Review of its Use in the Management of Serious Gram-Positive Infections

By Perry C.M.   Jarvis B.  

Drugs, Vol. 61, Iss. 4, 2001-01 ,pp. : 525-551

Adis International

Access to resources Recommend Favorite

Linezolid: In Infants and Children with Severe Gram-Positive Infections

By Lyseng-Williamson K.A.   Goa K.L.  

Pediatric Drugs, Vol. 5, Iss. 6, 2003-01 ,pp. : 419-429

Adis International

Access to resources Recommend Favorite

Telavancin: a novel lipoglycopeptide for serious Gram-positive infections

By Laohavaleeson Somvadee   Kuti Joseph L   Nicolau David P  

Expert Opinion on Investigational Drugs, Vol. 16, Iss. 3, 2007-03 ,pp. : 347-357

Informa Healthcare

Access to resources Recommend Favorite

Carbapenems in Serious Infections: A Risk-Benefit Assessment

By Ragnar Norrby S.  

Drug Safety, Vol. 22, Iss. 3, 2000-03 ,pp. : 191-194

Adis International

Access to resources Recommend Favorite